Products
Alextatug Biosimilar Monoclonal Antibody (PABPC1-Containing RNP Complex) for Research
Cat No.: GMP-Bios-INN-1072
Anti-RNP complex containing PABPC1 therapeutic antibody (Pre-made Alextatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Alextatug (development code ATRC-101) is a monoclonal antibody targeting a tumor-restricted extracellular ribonucleoprotein complex containing PABPC1. It is developed by Atreca for advanced solid tumors. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1072-1mg | 1mg | 3090 |
| GMP-Bios-INN-1072-10mg | 10mg | |
| GMP-Bios-INN-1072-100mg | 100mg | |
| GMP-Bios-INN-1072-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Alextatug biosimilar, Whole mAb, Anti-RNP complex containing PABPC1 Antibody: Anti-PABP/PABPC1/Polyadenylate-binding protein 1/PABP-1 therapeutic antibody |
| INN Name | Alextatug |
| Target | RNP complex containing PABPC1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Atreca |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Solid tumours |
| Production | na |
| Development Tech | na |
